x min read

Trader's Alert - Garmin Ltd. (NASDAQ:GRMN), Cara Therapeutics Inc (NASDAQ:CARA), Charter Communications, Inc. (NASDAQ:CHTR)

Trader's Alert - Garmin Ltd. (NASDAQ:GRMN), Cara Therapeutics Inc (NASDAQ:CARA), Charter Communications, Inc. (NASDAQ:CHTR)
Written by
Joel Najarian
Published on
October 29, 2014
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook
InsidrFinancial

Garmin Ltd. (NASDAQ:GRMN) reported Q3 revenue was up 10% over year ago levels to $706 million, well ahead of the analyst consensus of $679.7 million. Pro forma EPS was $0.76, up from $0.69 per share last year and four cents ahead of the Street view on Capital IQ. For the full year 2014, Garmin Ltd. (NASDAQ:GRMN) now expects revenue at about $2.85 billion, the high end of its prior guidance, with gross and operating margins of 56% and 24%, respectively. Pro forma EPS is forecast at $3.10 per share. The Street consensus stands at $2.81 billion in revenue and earnings of $3.09 per share.Cara Therapeutics Inc (NASDAQ:CARA), a biopharmaceutical company, announced positive results from its Human Abuse Liability (HAL) trial of an intravenous formulation of CR845, a pain medicine designed to prevent abuse. The trial of the peripherally-selective kappa opioid agonist met its primary endpoint with statistically significant reductions in scores for "drug liking," as well as "feeling high", "overall liking", and "take drug again" as compared to I.V. pentazocine, a Schedule IV opioid analgesic. The scores are measures recommended by the U.S. Food and Drug Administration to assess a drug's abuse liability, both for recommended scheduling as well as labeling."We are extremely pleased with the results from this human abuse liability trial, which suggest the potential for CR845 to be the first Schedule V or non-scheduled peripheral opioid for acute pain," said Derek Chalmers, Ph.D, D.Sc., President and Chief Executive Officer of Cara Therapeutics Inc (NASDAQ:CARA), "With positive analgesic efficacy data from two previous Phase 2 trials of I.V. CR845 and these positive HAL results now in hand, we look forward to advancing I.V. CR845 into Phase 3 clinical trials in early 2015."Charter Communications, Inc. (NASDAQ:CHTR), a broadband communications provider, reported a narrower Q3 loss on higher revenue. The company reported a Q3 loss per share of $0.49, narrower than the loss of $0.68 reported in Q3 2013 but missing analyst expectations of $0.02 in earnings for the quarter, if comparable. Total revenues of $2.28 billion were up from $2.11 billion in Q3 2103 in line with analyst projections of $2.28 billion. Residential customer relationships increased 68,000 during the third quarter, versus 46,000 during Q3 2013. Residential primary service units increased by 114,000 during the period, versus 100,000 in the year-ago quarter. Shares of Charter Communications, Inc. (NASDAQ:CHTR) are at $157.40 within a 52-week range of $116.78 - $167.30.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.